Alcon stock reports 8 percent sales growth in Q2 2026

Published on 09/25/2026 at 16:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon stock traded at USD 64.28 on September 25, 2026, while Q2 core EPS reached USD 0.84. Jefferies kept its USD 85.00 target on September 22.

Black and white photojournalism style. Ophthalmologist using slit-lamp biomicroscope to examine patient seated in optometry chair, strong chiaroscuro contrast, documentary grain, intimate clinical moment captured in wide horizontal frame — Alcon CH0432492467: Schwarz Weiß Fotografie eines Augenarztes mit Spaltlampe und Patient im Untersuchungsstuhl, Illustration mit AI erstellt.

Alcon stock (ISIN CH0432492467) was trading at USD 64.28 on NYSE on September 25, 2026 at 10:25 a.m. ET, down 0.43 percent from USD 64.56, while second-quarter sales rose 8 percent year over year to USD 2.78 billion. The latest analyst checkpoint came on September 22, 2026, when Jefferies reiterated its Buy rating and USD 85.00 price target, according to MarketBeat.

Q2 sales rise 8 percent

Alcon's Q2 2026 core earnings per share reached USD 0.84, up 10.5 percent from the year-ago quarter and 9.09 percent above the consensus estimate, The Globe and Mail reported on August 11, 2026.

The revenue mix was balanced across Alcon's main businesses: Surgical sales reached USD 1.57 billion and Vision Care sales USD 1.21 billion, with both segments up 8 percent year over year. Equipment and other Surgical sales grew 25 percent to USD 279 million, while Implantables increased 1 percent to USD 466 million.

Guidance rises as margins split

Management lifted 2026 core diluted EPS growth guidance to 12%-15% from 10%-13%, while maintaining its constant-currency net sales growth outlook at 5%-7%, according to The Globe and Mail.

The counterweight is profitability. Q2 gross margin expanded to 60.2 percent, yet operating margin fell to 0.4 percent after a PowerVision-related impairment charge, a 920-basis-point decline from the year-ago period. For investors, the central question is whether Unity-led equipment growth can offset slower Implantables growth while the impairment effect fades.

Stock sits below its yearly high

At USD 64.28, Alcon shares were 26.65 percent below the 52-week high of USD 87.64 and USD 2.44 above the 52-week low of USD 61.84 on September 25, 2026. Trading volume stood at 307,459 shares, against an indicated market capitalization of USD 31.35 billion.

Jefferies' USD 85.00 target places the analyst view above the current NYSE quote, while Alcon's next earnings release is scheduled for November 10, 2026, according to MarketScreener.